BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15319717)

  • 1. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.
    Naik AM; Fey J; Gemignani M; Heerdt A; Montgomery L; Petrek J; Port E; Sacchini V; Sclafani L; VanZee K; Wagman R; Borgen PI; Cody HS
    Ann Surg; 2004 Sep; 240(3):462-8; discussion 468-71. PubMed ID: 15319717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram.
    Park J; Fey JV; Naik AM; Borgen PI; Van Zee KJ; Cody HS
    Ann Surg; 2007 Mar; 245(3):462-8. PubMed ID: 17435554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
    Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
    Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 200 Sentinel lymph node biopsies without axillary lymph node dissection -- no axillary recurrences after a 3-year follow-up.
    Reitsamer R; Peintinger F; Prokop E; Rettenbacher L; Menzel C
    Br J Cancer; 2004 Apr; 90(8):1551-4. PubMed ID: 15083184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
    Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy.
    Langer I; Marti WR; Guller U; Moch H; Harder F; Oertli D; Zuber M
    Ann Surg; 2005 Jan; 241(1):152-8. PubMed ID: 15622003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.
    Han SN; Amant F; Cardonick EH; Loibl S; Peccatori FA; Gheysens O; Sangalli CA; Nekljudova V; Steffensen KD; Mhallem Gziri M; Schröder CP; Lok CAR; Verest A; Neven P; Smeets A; Pruneri G; Cremonesi M; Gentilini O;
    Breast Cancer Res Treat; 2018 Apr; 168(2):551-557. PubMed ID: 29235045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node biopsy alone without axillary lymph node dissection--follow up of sentinel lymph node negative breast cancer patients.
    Reitsamer R; Peintinger F; Prokop E; Menzel C; Cimpoca W; Rettenbacher L
    Eur J Surg Oncol; 2003 Apr; 29(3):221-3. PubMed ID: 12657230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stage migration in breast cancer: surgical decisions concerning isolated tumour cells and micro-metastases in the sentinel lymph node.
    de Widt-Levert L; Tjan-Heijnen V; Bult P; Ruers T; Wobbes T
    Eur J Surg Oncol; 2003 Apr; 29(3):216-20. PubMed ID: 12657229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of false-negative sentinel lymph nodes in breast cancer.
    Zavagno G; Del Bianco P; Koussis H; Artioli G; Carraro P; De Salvo GL; Mencarelli R; Belardinelli V; Marconato G; Nitti D
    Eur J Surg Oncol; 2008 Jun; 34(6):620-5. PubMed ID: 17764888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of additional lymph node involvement in breast cancer patients with positive sentinel lymph nodes.
    Pohlodek K; Bozikova S; Meciarova I; Mucha V; Bartova M; Ondrias F
    Neoplasma; 2016; 63(3):427-34. PubMed ID: 26925789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
    Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
    Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence.
    Port ER; Garcia-Etienne CA; Park J; Fey J; Borgen PI; Cody HS
    Ann Surg Oncol; 2007 Aug; 14(8):2209-14. PubMed ID: 17268882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the presence of sentinel lymph node macrometastases in breast cancer patients require axillary lymph node dissection?-Single-center analysis.
    Nowikiewicz T; Zegarski W; Pagacz K; Nowacki M; Morawiec-Sztandera A; Głowacka-Mrotek I; Sowa M; Biedka M; Kołacińska A
    Breast J; 2018 Sep; 24(5):724-729. PubMed ID: 29476570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
    Zavagno G; De Salvo GL; Scalco G; Bozza F; Barutta L; Del Bianco P; Renier M; Racano C; Carraro P; Nitti D;
    Ann Surg; 2008 Feb; 247(2):207-13. PubMed ID: 18216523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.